Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › ondansetron

ondansetron

6 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of ondansetron

62 trials tracked of ondansetron: 21 in phase 3 or 4 and 6 with published results. The most-cited published study has 558 citations.

62Trials tracked
21Phase 3 & 4
0Recruiting
6With published results
Phase distribution
Phase 4 11 Phase 3 10 Phase 2 23 Phase 1 4 Other / NA 14
  1. Phase 4 The CHECK Trial: A Comparison of Headache Treatment in the ED: Compazine Versus Ketamine Completed · 558 cited
  2. Phase 4 Acupuncture Point P6 Stimulation for Reduction of Nausea and Vomiting During Cesarean Completed · 37 cited
  3. Phase 3 A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting. Completed · 32 cited
  4. Phase 3 A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC Completed · 24 cited
  5. Phase 4 Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy Completed · 2 cited
  6. Phase 3 Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy Completed · 2 cited
Show 44 more trials
  1. Phase 4 Quality of Recovery After Dexamethasone, Ondansetron or Placebo Intrathecal Morphine Administration Completed
  2. Phase 4 Ondansetron for Bipolar Disorder and Alcohol Use Disorders Completed
  3. Phase 4 Pharmacogenomics and Post-Operative Nausea and Vomiting Completed
  4. Phase 4 Effects of Ondansetron in Obsessive-compulsive and Tic Disorders Completed
  5. Phase 4 Dexamethasone vs Ondansetron After Cesarean Delivery Completed
  6. Phase 4 A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC) Completed
  7. Phase 4 Antiemetic Prophylaxis for Postdischarge Nausea and Vomiting After Hip Arthroscopy Completed
  8. Phase 4 Aprepitant Versus Ondansetron in Preoperative Triple-therapy Treatment of Nausea and Vomiting Completed
  9. Phase 3 Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation Completed
  10. Phase 3 Transversus Abdominis Plane Block in Microsurgical Breast Recon w/Abdominal Free Flap in Breast CA Completed
  11. Phase 3 Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients Completed
  12. Phase 3 Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017) Completed
  13. Phase 3 Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients Completed
  14. Phase 3 A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208) Completed
  15. Phase 3 Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031) Completed
  16. Phase 2 Can Ondansetron Prevent Neonatal Abstinence Syndrome (NAS) in Babies Born to Narcotic-dependent Women Completed
  17. Phase 2 Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients Completed
  18. Phase 2 PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers Completed
  19. Phase 2 New Medication Treatment for Stimulant Dependence Completed
  20. Phase 2 Analgesic Effect of IV Acetaminophen in Tonsillectomies Completed
  21. Phase 2 Ondansetron vs Prochlorperazine for Nausea and Vomiting in the Emergency Department Completed
  22. Phase 2 Ondansetron Versus Aprepitant Plus Ondansetron for Emesis Completed
  23. Phase 2 Pilot Study to Assess Palonosetron Versus Ondansetron as Rescue Medication in Subjects That Develop Postoperative Nausea and Vomiting (PONV) in the Postanesthesia Care Unit (PACU) Completed
  24. Phase 2 Ondansetron, Alcohol Use, and Alcohol-Related Symptoms In HIV+ Persons Completed
  25. Phase 2 Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant Completed
  26. Phase 2 Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting Completed
  27. Phase 2 Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy Completed
  28. Phase 2 Capsaicin Cream as an Adjunctive Therapy for Nausea and Vomiting of Pregnancy Completed
  29. Phase 2 A Study of TAK-951 to Stop Adults Getting Nausea and Vomiting After Planned Surgery Completed
  30. Phase 2 E7 TCR T Cells for Human Papillomavirus-Associated Cancers Completed
  31. Phase 2 Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide Completed
  32. Phase 2 Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029) Completed
  33. Phase 2 Ondissolve in the Prophylaxis/Rescue of Radiation Induced Nausea and Vomiting Completed
  34. Phase 2 How Pregnant Women and Their Babies Metabolize Ondansetron Compared to a Group of Non-pregnant Women Completed
  35. Phase 2 Rolapitant as an Antiemetic in Malignant Glioma Patients Receiving Radiotherapy and Temozolomide Completed
  36. Phase 2 Pharmacogenetic Study of Ondansetron in Alcohol Use Disorder Completed
  37. Phase 2 The Effect of Ondansetron on Cardiac Output in Elective Cesarean Deliveries Completed
  38. Phase 2 A Study to Evaluate Aprepitant for the Prevention of Post-Operative Nausea and Vomiting in Children (MK-0869-219) Completed
  39. Phase 1 Ondansetron HCl Orally Disintegrating Tablets Under Non-Fasting Conditions Completed
  40. Phase 1 Ondansetron HCl Orally Disintegrating Tablets Under Fasting Conditions Completed
  41. Phase 1 Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183) Completed
  42. Phase 1 A Study of Aprepitant (MK-0869) in Pediatric Participants Undergoing Surgery (MK-0869-148) Completed
  43. N/A 5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence Completed
  44. N/A Prevention of Postoperative Nausea and Vomiting (PONV) in Surgical Patients Completed

Showing the 50 most-cited and recently-updated of 62 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Ondansetron home use for pediatric acute gastroenteritis vomiting after ED discharge
Pediatrics RCT
Ondansetron home use for pediatric acute gastroenteritis vomiting after ED discharge Children with vomiting after emergency visit face higher risk of return care
This secondary analysis of a randomized clinical trial in 977 children with acute gastroenteritis found that 8.6% had 3 or more vomiting epi…
Kids who keep vomiting after leaving the ER are much more likely to need follow-up care. This study found a strong link between ongoing vomi…
May 9, 2026
Liquid ondansetron at triage showed no benefit over placebo for reducing observation time in pediatric gastroenteritis
Pediatrics RCT
Liquid ondansetron at triage showed no benefit over placebo for reducing observation time in pediatric gastroenteritis Ondansetron at Triage Doesn’t Speed ER Discharge for Kids
This randomized controlled trial enrolled 91 children aged 6 months to 17 years with gastroenteritis presenting with more than 3 vomiting ep…
Giving anti-vomiting medicine early didn't reduce ER observation time for kids with stomach infections, though the study was too small to co…
medRxiv Apr 18, 2026
Electronic antiemetic device plus ondansetron improved delayed CINV response in 126 cancer patients
Oncology RCT
Electronic antiemetic device plus ondansetron improved delayed CINV response in 126 cancer patients A Wearable Buzz on Your Wrist May Ease Chemo Nausea
This single-centre randomized controlled trial enrolled 126 cancer patients receiving moderately or highly emetogenic chemotherapy.
A small device targeting an old acupressure point may give real relief from the days-long nausea that chemo drugs leave behind.
Apr 13, 2026
FDA Approves Ondansetron Injection, USP (ondansetron hydrochloride) for Prevention of Chemotherapy-Induced and Postoperative Nausea/Vomiting
Oncology FDA Approval
FDA Approves Ondansetron Injection, USP (ondansetron hydrochloride) for Prevention of Chemotherapy-Induced and Postoperative Nausea/Vomiting FDA approves a new preservative-free injection to prevent nausea and vomiting from chemotherapy and surgery
FDA approved ondansetron injection for prevention of nausea/vomiting associated with emetogenic cancer chemotherapy and postoperative nausea…
FDA approves a new preservative-free injection to prevent nausea and vomiting from chemotherapy and surgery.
FDA Apr 10, 2026
Network meta-analysis compares 5-HT3 antagonists with or without dexamethasone for highly emetogenic chemotherapy-induced nausea and vomiting
Oncology Meta-analysis
Network meta-analysis compares 5-HT3 antagonists with or without dexamethasone for highly emetogenic chemotherapy-induced nausea and vomiting New analysis suggests palonosetron plus dexamethasone may reduce delayed vomiting in chemotherapy patients
This network meta-analysis evaluated 5-hydroxytryptamine-3 (5-HT3) receptor antagonists with or without dexamethasone in patients undergoing…
Combining palonosetron with dexamethasone reduces delayed vomiting in chemotherapy patients better than other common drug options.
Apr 9, 2026
Ondansetron Slightly Prolongs QTc Interval in Pediatrics Without Dysrhythmia Risk
Pediatrics Meta-analysis
Ondansetron Slightly Prolongs QTc Interval in Pediatrics Without Dysrhythmia Risk Is Ondansetron Safe for Kids? New Insights on Heart Health
Meta-analysis shows ondansetron increases QTc by 4.7 ms (95% CI 1.4-8.1) in healthy children, with no dysrhythmia risk.
While ondansetron slightly changes heart measurements in kids, serious rhythm problems are extremely rare, making it a safe option for treat…
Mar 27, 2026